BREAKTHROUGH CLINICAL RESULTS ON HYPOGLYCAEMIA REDUCTION

BREAKTHROUGH CLINICAL RESULTS ON HYPOGLYCEMIA REDUCTION

Breakthrough clinical results on hypoglycemia reduction

MiniMed™ Veo with Low Glucose Suspend (LGS)*: The only system clinically proven to significantly reduce hypoglycemia events1-2

Automation to Simulate Pancreatic Insulin Response (ASPIRE) IN-HOME STUDY
 

R. BERGENSTAL, USA1

New England Journal of Medicine - June 2013

MiniMed Veo System with LGS vs. Sensor augmented pump

  • 32% reduction of night-time hypo
    events
  • 38% reduction of night-time AUC

Without deterioration of HbA1c

SEVERE HYPO STUDY

 

 

 

T. LY, AUSTRALIA2

ADA - June 2013

MiniMed Veo System with LGS vs.
CSII

  • 0 Severe hypo events (seizure or
    coma)
  • Reduced fear of hypo

Without deterioration of HbA1c

Did you know that...?

  • On average, a patient experiences4
    - 2 symptomatic hypos per week
    - >1 severe hypo per year
  • 74% of Type 1 patients report altering insulin doses out of fear of hypoglycemia3.
Canadian Diabetes Association 2013 Clinical Practice Guidelines

According to the 2013 CDA Clinical Practice Guidelines (www.guidelines.diabetes.ca), for people living with type 1 diabetes, CGM may be used to improve glycemic control and reduce hypoglycemia5.

 

George, in better control with his pump since 2010

CGM with MiniMed Veo has made a massive difference for me. An alarm alerts me if my levels are too low. At night, if I don't hear the alarm when I go low, my MiniMed Veo will automatically suspend my insulin to reduce my hypos. With Type 1 diabetes you never know how the day will turn out: my pump and CGM gives me better control.

References
  1. R.M. Bergenstal, Threshold-Based Insulin-Pump Interruption for Reduction of Hypoglycemia, N Engl J Med 2013; 369:224-232 July 18, 2013
  2. Ly T.T, Nicholas J.A., Retterath A. et al. Reduction of Severe Hypoglycemia with Sensor-Augmented Insulin Pump Therapy and Automated Insulin Suspension in Patients with Type 1 Diabetes [abstract]. Diabetes 2013; 62 (supplement 1): 228-OR
  3. Fidler C, Elmelund CT , Gillard S. Hypoglycemia: an overview of fear of hypoglycemia, quality-of-life, and impact on costs. J Med Econ. 2011; 14(5):646-655.
  4. Cryer PE. The barrier of hypoglycemia in diabetes. Diabetes. 2008 Dec; 57(12):3169-76
  5. Canadian Diabetes Association Clinical Practice Guidelines Expert Committee. Canadian Diabetes Association 2013 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada. Can J Diabetes 2013;37(suppl 1):S1-S212
  • **LGS and CGM require the use of the MiniLink™ transmitter and glucose sensors (sold separately).